Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 6Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Primary Myelofibrosis 1Pancreatic Neoplasms 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Genital Neoplasms, Male 1Genital Diseases, Male 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Hepatocellular 1

Interventions

Peripheral Blood Stem Cell Transplantation 10Azacitidine 10fludarabine phosphate 8Whole-Body Irradiation 8Cyclosporine 7ruxolitinib 6Mycophenolic Acid 6Busulfan 6Methotrexate 5Cyclophosphamide 5fludarabine 4Tacrolimus 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 3Alemtuzumab 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2eprenetapopt 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Docetaxel 2Cord Blood Stem Cell Transplantation 2tipifarnib 1sonidegib 1rucaparib 1quizartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myeloproliferative Disorders × abiraterone × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡